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Background. The majority of infants will not be protected by maternal antibodies until their first measles vaccination, between 
12 and 15 months of age. This provides incentive to reduce the age at measles vaccination, but immunological consequences are in-
sufficiently understood, and long-term effects are largely unknown.
Methods. A total of 79 infants who received early measles vaccination between 6 and 12  months age and a second dose at 
14 months of age were compared to 44 children in a control group who received 1 dose at 14 months of age. Measles virus–specific 
neutralizing antibody concentrations and avidity were determined up to 4 years of age.
Results. Infants who first received measles vaccination before 12 months of age had a long-term decrease in the concentration 
and avidity of measles virus–specific neutralizing antibodies, compared with infants in the control group. For 11.1% of children with 
a first dose before 9 months of age, antibody levels at 4 years of age had dropped below the cutoff for clinical protection.
Conclusions. Early measles vaccination provides immediate protection in the majority of infants but yields a long-term decrease 
in neutralizing antibody responses, compared to vaccination at a later age. Additional vaccination at 14 months of age does not im-
prove this. Over the long term, this may result in an increasing number of children susceptible to measles.
Keywords.  Antibody response; timing of vaccination; protection; antibody avidity.
Since the introduction of measles vaccination, the annual number 
of measles cases worldwide has notably dropped, with <10 mil-
lion cases in 2016 [1]. Still, the number of annual measles deaths 
was estimated to be 109 638 in 2017 [2]. Recent reports show an 
increase in the number of measles cases in several regions, with a 
record amount of cases in Europe in 2018 [1, 3–5]. Here, a large 
proportion of measles cases (range, 15.9%–32.0%) was reported 
in infants <1 year of age [6–8], a group at high risk for the devel-
opment of measles-related complications and mortality [9, 10].
At birth, infants are protected from measles by neutralizing 
maternal antibodies, the levels of which decline over time [11–
14]. These antibodies interfere with vaccine responses, which is 
a major reason to postpone vaccination until after the first year 
of life [15, 16]. Importantly, recent studies showed that measles 
virus–specific maternal antibodies from vaccinated mothers 
only protect infants until 3–4 months of age and are no longer 
detectable in the majority of infants at 6 months of age [12, 14]. 
Despite this, vaccination at 6 months of age as compared to 12 
or 15 months of age results in lower seroconversion rates and 
lower levels of neutralizing antibodies shortly after vaccina-
tion [16, 17]. Although the early loss of maternal antibodies is 
a major incentive to reduce the age at first measles vaccination, 
especially in outbreak settings, long-term effects on measles 
virus–specific immunity and protection are largely unknown.
During the latest measles epidemic in the Netherlands, 
infants between 6 and 12 months of age living in areas with a 
vaccination coverage <90% were offered an additional measles 
vaccination prior to regular vaccination at 14 months [18]. This 
provided the opportunity to perform a clinical study to inves-
tigate the humoral immune response over the short and long 
term in relation to the timing of the first measles vaccination.
METHODS
Study Population
During a measles epidemic in the Netherlands from May 2013 
until March 2014, parents were invited to enroll their infants 
in a prospective observational cohort study from week 35 of 
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2013 up to week 8 of 2014 [19]. In the online baseline question-
naire of this study, parents could indicate whether they could be 
approached for future research. Parents who agreed to this re-
ceived an invitation to join this controlled, open-label, parallel-
group trial. A total of 79 healthy infants at the time of inclusion 
who received a first dose of measles, mumps, and rubella vac-
cine (MMR) between 6 and 12  months of age and a second 
dose at 14 months of age (hereafter, “MMR-1” denotes MMR 
received at age 14 months) were included. A control group of 
44 infants who received only MMR-1 was selected from the 
Dutch community-based administration. Informed consent 
was obtained from parents. Blood specimens were collected 
through heel/finger prick or venipuncture during home visits 
at 14 months of age, before MMR-1 receipt, and then 6 weeks, 
1 year, and 3 years later (Figure 1). Parents filled out a question-
naire. Exclusion criteria were receipt of immunosuppressive 
medication, presence of a known or suspected immunological 
or bleeding disorder, and assumed previous measles virus infec-
tion (based on positive results of serologic testing), which is why 
2 children were excluded from the control group. The study was 
approved by the Medical Research Ethics Committees United 
(METC Noord-Holland, Alkmaar, the Netherlands; clinical 
trials registration NL45616.094.13).
Measles Vaccination
Before enrollment, infants had already received MMR-VaxPro vac-
cine (RVG 17672; Sanofi Pasteur-MSD), containing live attenuated 
measles virus (Enders’ Edmonston strain), mumps virus (Jeryl 
Lynn [level B] strain), and rubella virus (Wistar RA 27/3 strain), be-
tween 6 and 12 months of age. The same vaccine was administered 
to all children at 14 months of age during a home visit.
Laboratory Analysis
Serum samples were obtained from whole-blood specimens and 
stored at −20°C until use. Measles virus–specific neutralizing 
antibodies were measured in a modified plaque reduction neu-
tralization test endorsed by the World Health Organization 
(WHO) [20]. Two-step serum dilution series were made in 
triplicate in 96-well culture plates. The WHO 3rd International 
Standard for measles virus antibody (3 IU/mL; NIBSC code 
97/648) was included. Incubation with laboratory-adapted 
Edmonston virus and Vero cells was performed according 
to a previously established protocol [21, 22]. Measles virus–
infected foci were stained after 48 hours with anti-measles 
virus nucleoprotein antibody (clone 83KKII; Merck Millipore). 
Measles virus–specific neutralizing antibody concentrations are 
expressed as IU/milliliter, based on the 50% plaque reduction 
dilution of the serum and standard. A concentration of ≥0.12 
IU/mL was considered to be protective [21, 23].
Measles virus–specific immunoglobulin G (IgG) avidity was 
determined by modifying an established bead-based multiplex 
immunoassay for measles virus serum IgG [24]. Briefly, after 
incubation of measles virus–conjugated fluorescent beads with 
serum and before staining, beads were washed with phosphate-
buffered saline and subsequently left untreated or treated for 
10 minutes with 1.5 M ammonium thiocyanate (NH4SCN; 
Merck Millipore). This condition showed a separation between 
low- and high- avidity samples comparable to that in pre-
viously published assays [25]. The avidity index is defined as 
the percentage of antibodies that remain bound to the beads 
after treatment with NH4SCN, calculated as: [amount of IgG 
after NH4SCN treatment]/[amount of IgG without NH4SCN 
treatment] × 100.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism (ver-
sion 7.03), R package 3.4.4, and IBM SPSS statistics (version 
24). The geometric mean measles virus–specific neutralizing 
antibody concentration (GMC) and geometric mean avidity 
index were calculated. For statistical analysis, individual 
Early vaccination
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Figure 1. Study design. Children were grouped on the basis of age at first receipt of measles, mumps, and rubella (MMR) vaccine: 6–8 months, 9–12 months, or 14 months. 
Ages at which blood samples were collected are indicated, as are the number of withdrawals recorded at each home visit. Numbers in colored boxes indicate the number of 
samples analyzed for each group at each time point. MMR-1, MMR dose received at age 14 months.
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measles virus–specific neutralizing antibody concentrations 
were log10 transformed. Children were grouped on the basis of 
their age at first receipt of the vaccine. Differences in the per-
centage of protected children were calculated using the Fisher 
exact test. Differences between GMCs of groups were tested by 
the Kruskal-Wallis test and corrected for multiple comparisons 
by using the Dunn test. The Friedman test was performed to 
analyze differences over time. Children with missing data from 
≥1 time point were excluded.
We fitted a linear model to log10-transformed antibody levels, 
which gives a constant fraction of antibodies disappearing over 
time, assuming that the antibody decay rate per individual 
was constant. The exponential decay rate was determined 
by fitting a linear mixed-effects random intercept regression 
model [26] on log(neutralizing antibody concentrations) for 
all children 6 weeks, 1 year, and 3 years after receipt of MMR-
1. Early vaccinated children with antibody levels of ≤0.12 IU/
mL at 14 months of age were excluded. The model accounts for 
differences in the antibody concentration (the random inter-
cept) between infants. Age groups, time after MMR-1 receipt, 
and an interaction term between these variables were added as 
fixed effects in the model to account for a possible difference in 
the rate of exponential decay by age group.
P values ≤.05 indicate statistically significant differences.
RESULTS
Study Characteristics
In total, 79 children who received a first vaccine dose between 
ages 6 and 12 months and a second dose (ie, MMR-1) at age 
14 months were included in the study, together with a control 
group of 44 children who received only MMR-1. Three years 
after MMR-1 receipt, parents were approached again for inclu-
sion, which resulted in a relatively large withdrawal proportion 
of 25% (23 of 113 children; Figure 1). Group sizes were rather 
similar at this time point, and neutralizing antibody GMCs 
were comparable at all time points between the full cohort and 
children who completed the study at 4 years of age (data not 
shown). This implies that the children who withdrew from the 
study created no bias.
Baseline characteristics of early vaccinated children and 
the control group are shown in Table 1. All groups were com-
parable with respect to period of birth, sex, birth year of 
mothers, duration of pregnancy, and percentage of mothers 
breastfeeding their children, except that, among mothers of 
infants in the early vaccinated groups, a greater proportion re-
ceived measles vaccine (P = .001) but a smaller proportion had 
measles (P = .045) during childhood, compared with mothers 
of infants in the control group. Although we have no expla-
nation for these differences, we assume that the higher per-
centage of children born to naturally infected mothers in the 
control group did not influence our results, because maternal 
antibodies are not expected to be present [14] and were not 
detected at 14 months of age.
MMR Receipt Before 9 Months of Age Resulted in Decreased Neutralizing 
Antibody Concentrations
Measles virus–specific neutralizing antibody concentrations 
were determined at 14 months of age and 6 weeks, 1 year, and 
3  years later (Supplementary Table 1). Measles virus–specific 
neutralizing antibody concentrations relative to age (in days) 
at receipt of MMR are shown for each individual child in 
Supplementary Figure 1A–D.
Table 1. Baseline Characteristics
Characteristic
Age at Primary Vaccination
P 6–8 mo (n = 44) 9–12 mo (n = 31) 14 mo (Control) (n = 40)
Birth date 21 Dec 2012 (2 Nov 2012–25 Jul 2013) 2 Sep 2012 (2 Aug 2012–27 Sep 2012) 15 Jun 2013 (8 Aug 2012–23 Aug 2013)  
Male sex 19 (43.2) 15 (48.4) 17 (42.5) .867a
Birth year of mother 1982 (1971–1989] 1982 (1967–1989) 1982 (1971–1988) .545b
Pregnancy duration, wka 39.5 (31–42] 39 (29–42) 40 (36–44) .310b
Breastfeedingb     
 Yes 24 (54.5) 13 (41.9) 18 (45.0) .508a
 No 20 (45.5) 18 (58.0) 22 (55.0)  
Childhood measles in mother     
 Yes 5 (11.4) 5 (15.2) 14 (35.0) .045a
 No 29 (65.9) 19 (61.3) 23 (57.5)  
 Unknown 10 (22.7) 7 (22.6) 3 (7.5)  
Measles vaccine receipt by mother     
 Yes 38 (86.4) 25 (80.6) 26 (65) .001a
 No 2 (4.5) 2 (6.5) 13 (32.5)  
 Unknown 4 (9.1) 4 (12.9) 1 (2.5)  
Data are median (range) or no. (%) of infants.
aBy the χ2 test.
bBy the Kruskal-Wallis test.
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Group-wise analysis revealed that, before receipt of MMR-1, 
children who received their first dose between 6 and 8 months 
of age had lower measles virus–specific neutralizing antibody 
GMCs than children who received their first dose between 9 and 
12 months of age (P = .002; Figure 2A). All children vaccinated be-
tween 9 and 12 months of age had antibody concentrations above 
the cutoff for clinical protection, whereas 20% of children (9 of 
45) vaccinated between ages 6 and 8 months did not (P = .001).
Six weeks after MMR-1 receipt, measles virus–specific 
neutralizing antibodies were detected in all children from the 
control group except 1 (2.5%), which can be considered a pri-
mary vaccination failure (Figure 2B). Unfortunately, no follow-up 
samples were available because this child withdrew from the study. 
At this time, GMCs were higher in the control group as compared 
to those in children with a first dose between ages 6 and 8 months 
(P  =  .057) and 9–12  months (P  =  .025). All early vaccinated 
children had antibody levels above the cutoff for protection.
One and 3  years after receipt of their last vaccine dose, 
a downward trend was observed in neutralizing antibody 
concentrations, which was strongest for children who received a 
first dose between ages 6 and 8 months. While the differences at 
these later time points between the control group and children 
first vaccinated between 9 and 12 months of age were not sig-
nificant (P = .13 for comparisons at each time point), children 
who received the first dose between ages 6 and 8 months had 
clearly lower GMCs (P < .0001; Figure 2C and 2D). No distinc-
tion could be made between early vaccinated children who re-
ceived their first dose between ages 6 and 8 months and 9 and 
12 months 1 year (P = .14) and 3 years after MMR-1 (P = .08). 
All children with a first dose between ages 9 and 12  months 
and the control group had measles virus–specific neutralizing 
antibodies that were still above the cutoff for protection 3 years 
after receipt of their last dose. One year after MMR-1 receipt, 1 
child (2.6%) who received a first dose between 6 and 8 months 
of age had measles virus–specific neutralizing antibodies below 
the cutoff for protection, which increased to 3 children (11.1%) 
3 years after MMR-1 receipt (P = .111 for the comparison be-
tween early vaccine recipients aged 6–8 months and the control 
group). For all groups and time points analyzed, no sex-based 
differences were observed (data not shown).
MMR Receipt Before 12 Months of Age Resulted in Lower Antibody Avidity
Differences in neutralizing antibody concentrations between 
groups increased over time, which may indicate differences in 
antibody avidity maturation. We compared antibody avidity 1 
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Figure 2. Measles virus–specific neutralizing antibodies measured by a focus reduction neutralization test (FRNT) in children who received their first measles, mumps, and 
rubella vaccine (MMR) dose at 6–8 months, 9–12 months, or 14 months of age. Differences in geometric mean concentrations between groups, represented as horizontal 
bars, were compared by the Kruskal-Wallis test at 14 months of age (A) and then 6 weeks (B), 1 year (C), and 3 years later (D). The dashed gray line indicates the level of 
antibody sufficient for protection from clinical measles (ie, 0.12 IU/mL). Two controls assumed to have measles, based on positive serologic test results at 14 months of age, 
were excluded from analysis. MMR-1, MMR dose received at age 14 months. *P ≤ .05, **P ≤ .01, and ****P ≤ .0001.
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Figure 3. Avidity of measles virus–specific immunoglobulin G (IgG) in children 
who received their first measles, mumps, and rubella vaccine (MMR) dose at 
6–8  months, 9–12  months, or 14  months of age. Avidity was measured 1 and 
3  years after receipt of vaccine at 14  months of age. Horizontal bars represent 
geometric mean values, which were compared by the Kruskal-Wallis test. MMR-1, 
MMR dose received at age 14 months. **P ≤ .01.
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and 3 years after receipt of the last vaccine dose, to represent 
time points of more complete avidity maturation [27] (Figure 
3). After 1 year, we did not observe any differences (Figure 3A), 
but after 3  years, early vaccinated children had antibodies of 
lower avidity than children with a first dose at 14  months of 
age (P = .07 and P = .005 for comparisons between the control 
group and infants with the first dose at ages 6–8 months and 
9–12  months, respectively; Figure 3B). We did not observe a 
correlation between neutralizing antibody concentrations and 
avidity index (data not shown).
MMR-1 Receipt Only Temporarily Increased Antibody Concentrations in 
Children First Vaccinated Before 9 Months of Age
Next, we studied individual longitudinal dynamics and 
observed different response patterns between the groups 
(Figure 4). Children first vaccinated between 6 and 8 months 
of age showed an increased neutralizing antibody titer within 
6 weeks after the second dose of measles vaccine (Figure 4A). 
However, antibody levels significantly dropped in the subse-
quent 3 years, some of which decreased to levels observed be-
fore receipt of MMR-1. This became more apparent when the 6 
children who had no protective antibody levels before receipt 
of MMR-1 were excluded from analysis (Figure 4D). These 
6 children showed a strong increase in neutralizing antibody 
levels after MMR-1 receipt, comparable to the control group 
(Figure 4C and 4D). Antibody levels in children who received 
their first dose between 9 and 12 months of age increased only 
slightly after receipt of MMR-1 and declined in the subsequent 
3 years (Figure 4B).
The antibody responses after vaccination between 6 and 
8 months were predictive for the long-term responses following 
receipt of MMR-1, but only for children who had responded to 
the first dose (Figure 5A and 5B). This correlation was not as 
strong for children who received their first dose between 9 and 
12 months of age (Figure 5C).
Antibody Concentrations Declined Faster After Early Vaccination
Because of the individual variability in the decline of antibody 
levels following measles vaccination, we applied mixed mod-
eling to calculate the exponential decay of the antibody re-
sponse until 9 years of age (Figure 6). At this time point, Dutch 
children normally receive their second measles vaccination. For 
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Figure 4. A–C, Individual measles virus–specific neutralizing antibody concentrations over time for children who first received measles, mumps, and rubella vaccine (MMR) 
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at 14 months of age and then 6 weeks, 1 year, and 3 years later and then compared by the Friedman test. The bold lines represent geometric mean concentrations for each 
group. *P ≤ .05, **P ≤ .01, ***P ≤ .001, and ****P ≤ .0001.
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/220/4/594/5441452 by Erasm
us U
niversiteit R
otterdam
 user on 11 D
ecem
ber 2019
Ab Responses After Early Measles Vaccination • jid 2019:220 (15 August) • 599
children who received a first dose between 9 and 12  months 
of age, antibodies decreased at a faster rate per month (log 
value, −0.01) than those of the control group, but this differ-
ence was not significant (Supplementary Table 2). Based on this 
model, antibody levels were also expected to remain above the 
threshold for protection until the next vaccination. However, 
children who received a first dose between 6 and 8 months of 
age showed a faster decay of their antibodies per month (log 
value, −0.03; P < .01) as compared to the control group, and the 
model predicted that, 5 years after MMR-1 receipt, antibodies 
will have dropped below the threshold for protection.
DISCUSSION
In this study, we showed that most children develop protec-
tive measles virus–specific antibodies following vaccination 
as early as 6 months of age. A lower risk of measles virus in-
fection was indeed shown for infants first vaccinated between 
6 and 14  months of age during this measles outbreak [19]. 
Because low numbers of measles cases were reported, vac-
cine effectiveness could not accurately be determined; how-
ever, all reported measles cases occurred in infants vaccinated 
before 9  months of age [19]. We found that 20% infants 
vaccinated before 9 months of age had measles virus–specific 
neutralizing antibody levels below the cutoff for clinical pro-
tection (0.12 IU/mL), which highlights that a proportion of 
these infants is not sufficiently protected after 1 dose of MMR. 
It should be noted that the interval between early vaccination 
and antibody level measurement at age 14 months increased 
with a lower age at receipt of the first dose, which may account 
for some of the quantitative differences between the 2 early 
vaccinated groups.
Interestingly, for the subgroup of children with low levels 
of neutralizing antibodies after receipt of the first MMR dose, 
the response to MMR-1 was quite similar to that for the control 
group, indicating a primary antibody response after a receipt 
of MMR-1. This finding was substantiated by the observation 
that, at 4  years of age, all children had antibody levels above 
the cutoff for protection. Gans et al also showed that additional 
vaccination 12 months after primary vaccine failure at 6 months 
of age resulted in protective antibody levels 2 years later [16]. 
These results stress that additional vaccination is essential to 
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protect infants who do not respond to a first dose received be-
fore 9 months of age.
Previous studies have shown that vaccination before 
9 months of age induces a reduced antibody response [16, 17]. 
Recently, Carazo Perez et al showed that measles virus–specific 
vaccine response rates increase with increasing age at first vac-
cination, an effect that persists after additional vaccination [28]. 
However, another study showed a comparable response to a first 
dose of MMR received at 8 versus 12 months of age, based on 
measles virus–specific antibodies measured by enzyme-linked 
immunosorbent assay [29].
We showed an increased decline in the neutralizing an-
tibody concentration after additional vaccination in early 
vaccinated children as compared to the control group. This 
was clearly observed 3 years after vaccination, when antibody 
concentrations for 11.1% of children were found to have dropped 
below the cutoff for clinical protection. Previous studies show 
conflicting results about long-term protection after early vacci-
nation [30, 31], which may be partially explained by the use of 
different vaccines and different study designs and populations. 
However, long-term effects are of specific concern, as a gradual 
decrease in neutralizing antibody concentrations may result in 
increasing numbers of unprotected individuals in the popula-
tion over the long term.
MMR-1 receipt seems to have had little effect in children who 
received their first dose between 9 and 12 months of age. Here, 
the time between the first and second dose may have been crit-
ical; hence, we cannot exclude the possibility that postponing 
the second vaccination to later time points may result in 
increased antibody levels.
It should be noted that the effects of first vaccination between 
ages 9 and 12  months were still not similar to those of first 
vaccination at 14  months of age. Children first vaccinated at 
14 months of age had approximately twice the amount of mea-
sles virus–specific neutralizing antibodies, but this difference 
was not statistically significant, possibly because of the rela-
tively small sample size. Furthermore, antibody avidity was sig-
nificantly higher for children from the control group at 4 years 
of age, even though this did not reach statistical significance 
for children with a first dose between 6 and 8 months of age. 
This may be caused by the relatively small differences in avidity 
indexes between the groups and by the small sample size. Nair 
et al showed no differences between antibody avidity with re-
spect to the age at first vaccination [32], although avidity was 
measured only 6 months after the last vaccination. Similarly, we 
did not find any differences in avidity up to 1  year after vac-
cination between the early vaccinated groups and controls, 
indicating that this period is too short to measure differences in 
antibody avidity. Together, our results indicate that differences 
between groups become larger over time. Even though the ma-
jority of children are still protected 3 years after their last vacci-
nation, this may not be the case at a later age.
The reduced vaccine response in the early vaccinated group, 
especially for the 9 children who showed a low response at 
14  months of age, may be explained by the presence of ma-
ternal antibodies at the time of vaccination. Unfortunately, we 
were unable to investigate this because children were included 
after early vaccination, to avoid interference with the decision 
to vaccinate. However, a large cross-sectional serologic study 
performed in the Netherlands in 2006 showed that, on average, 
infants had maternal antibody levels below the protective level 
at 3.3 months of age, so we did not expect maternal antibodies to 
be present after 6 months of age [14]. In addition, the majority 
of mothers of early vaccinated infants were vaccinated during 
childhood, resulting in lower levels of maternal antibodies in 
their infants [19]. For these reasons, we expect that the influ-
ence of maternal antibodies on vaccination responses after 
6 months was negligible.
Gans et al showed that children first vaccinated at 6 months 
of age in the absence of maternal antibodies had a reduced an-
tibody response, compared with children first vaccinated at 9 or 
12 months of age [16]. This suggests a negative influence of the 
developing infant immune system on the vaccine response after 
early vaccination [33]. It is known that infants have fewer and 
less functional dendritic cells [34], and the number of dendritic 
cells has been positively correlated with the measles virus–spe-
cific antibody response [35]. Second, the neonatal immune 
system is generally thought to be skewed toward a T-helper 
type 2 response, because fewer T-helper type 1 cytokines are 
produced [36]. As a consequence, reduced dendritic cell priming 
and an altered T-cell response may result in suboptimal B-cell 
activation. This is supported by the observations that antibody 
responses changed qualitatively and quantitatively over time.
Several studies have shown a nonspecific beneficial effect 
on infant mortality after measles vaccination, as reviewed by 
Higgins et al [37]. We do not have information about morbidity 
or mortality in our cohort. Based on the small cohort size and 
the low childhood mortality rate in the Netherlands, we do not 
expect to be able to measure any nonspecific beneficial effects 
of early measles vaccination in this setting. However, for future 
decisions about the timing of measles vaccination, these non-
specific beneficial effects should be taken into consideration.
In conclusion, the majority of children who received early 
MMR vaccination still had protective antibody levels at 14 
months of age. This is expected to protect infants in an out-
break setting. However, reducing the age at first measles vac-
cination should be carefully assessed on an individual basis, 
owing to concerns about long-term protection against measles: 
because the susceptibility to measles virus infection among 
early vaccinated individuals may increase with age, herd im-
munity in the population might be adversely impacted. This 
notion is supported by the observations that, in a proportion 
of children first vaccinated at <9 months of age, antibody levels 
had already dropped below the cutoff of clinical protection at 
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4 years of age even though the children had been vaccinated 
twice. Reduced protection in early vaccinated individuals may 
contribute to an already decreasing level of vaccination cov-
erage and increase the risk of future epidemics.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors 
to benefit the reader, the posted materials are not copyedited 
and are the sole responsibility of the authors, so questions or 
comments should be addressed to the corresponding author.
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